The effects of leucine, its metabolites, and the 2-oxo acids of valine and isoleucine on protein synthesis and degradation in incubated limb muscles of immature and adult rats were tested. Leucine stimulated protein synthesis but did not reduce proteolysis when leucine transamination was inhibited. 4-Methyl-2-oxopentanoate at concentrations as low as 0.25mM inhibited protein degradation but did not change protein synthesis. The 2-oxo acids of valine and isoleucine did not change protein synthesis or degradation even at concentrations as high as 5mM. 3-Methylvalerate, the irreversibly decarboxylated product of 4-methyl-2-oxopentanoate, decreased protein degradation at concentrations > 1 mm. This was not due to inhibition of 4-methyl-2-oxopentanoate catabolism, because 0.5 mM-3-methylvalerate did not suppress proteolysis, even though it inhibited leucine decarboxylation by 30%; higher concentrations of 3-methylvalerate decreased proteolysis progressively without inhibiting leucine decarboxylation further. During incubation with [1-14C]-and [U-14C]-leucine, it was found that products of leucine catabolism formed subsequent to the decarboxylation of 4-methyl-2-oxopentanoate accumulated intracellularly. This pattern was not seen during incubation with radiolabelled valine. Thus, the effect of leucine on muscle proteolysis requires transamination to 4-methyl-2-oxopentanoate. The inhibition of muscle protein degradation by leucine is most sensitive to, but not specific for, its 2-oxo acid, 4-methyl-2-oxopentanoate.
The effects of leucine, its metabolites, and the 2-oxo acids of valine and isoleucine on protein synthesis and degradation in incubated limb muscles of immature and adult rats were tested. Leucine stimulated protein synthesis but did not reduce proteolysis when leucine transamination was inhibited. 4-Methyl-2-oxopentanoate at concentrations as low as 0.25mM inhibited protein degradation but did not change protein synthesis. The 2-oxo acids of valine and isoleucine did not change protein synthesis or degradation even at concentrations as high as 5mM. 3-Methylvalerate, the irreversibly decarboxylated product of 4-methyl-2-oxopentanoate, decreased protein degradation at concentrations > 1 mm. This was not due to inhibition of 4-methyl-2-oxopentanoate catabolism, because 0.5 mM-3-methylvalerate did not suppress proteolysis, even though it inhibited leucine decarboxylation by 30%; higher concentrations of 3-methylvalerate decreased proteolysis progressively without inhibiting leucine decarboxylation further. During incubation with [1-14C]-and [U-14C]-leucine, it was found that products of leucine catabolism formed subsequent to the decarboxylation of 4-methyl-2-oxopentanoate accumulated intracellularly. This pattern was not seen during incubation with radiolabelled valine. Thus, the effect of leucine on muscle proteolysis requires transamination to 4-methyl-2-oxopentanoate. The inhibition of muscle protein degradation by leucine is most sensitive to, but not specific for, its 2-oxo acid, 4-methyl-2-oxopentanoate.
Branched-chain amino acids have unique anabolic effects on muscle protein metabolism. For example, in perfused hearts, the stimulation of protein synthesis attained with a complete mixture of amino acids was achieved with branched-chain amino acids alone (Morgan et al., 1971; Rannels et al., 1974) . In incubated and perfused skeletal muscle, protein synthesis could be stimulated by leucine but not by valine or isoleucine (Buse & Reid, 1975 ; Buse & Weigand, 1977; Fulks et al., 1975; Li & Jefferson, 1978; Tischler et al., 1982) . Leucine also inhibited protein degradation in incubated skeletal muscle of immature rats (Buse & Reid, 1975; Fulks et al., 1975) and in perfused rat hearts (Chua et al., 1979) . However, in perfused hindquarters of adult rats, leucine did not reduce protein degradation (Li & Jefferson, 1978) .
In studying the mechanism of these anabolic effects of leucine, Tischler et al. (1982) found that the degree of inhibition of protein degradation in rat hemidiaphragms increased with increasing concentrations of leucine in the incubation media and in the intracellular space. Chua et al. (1979) reported that high levels of the decarboxylated products of leucine, valine, and isoleucine decreased protein degradation in perfused rat hearts, but only the decarboxylated products of leucine and valine stimulated protein synthesis. Thus, the degradation of branched-chain amino acids and/or the intracellular accumulation of one or more of their catabolic products appear to be necessary for suppression of proteolysis. Indeed, Tischler et al. (1982) found that after inhibiting branched-chain amino acid transamination, leucine no longer decreased protein degradation in incubated rat hemidiaphragms, though protein synthesis was still stimulated by leucine. They also reported that an increased rate of leucine decarboxylation was associated with progressive suppression of muscle proteolysis. Since branched-chain amino acids share common transamination and decarboxylation pathways (Odessey & Goldberg, 1979;  Vol. 222 Smith et al., 1983) and products of branched-chain 2-oxo acid catabolism reduce protein degradation in perfused hearts (Chua et al., 1980) , it is unclear why proteolysis is suppressed in hemidiaphragms incubated with leucine but not with valine or isoleucine (Buse & Reid, 1975; Fulks et al., 1975; Tischler et al., 1982) . Differences in the metabolism of branched-chain amino acids in cardiac muscle and in diaphragm and other types of skeletal muscle (Veerkamp & Wagenmakers, 1981) might account for this. Therefore, we studied the effect of 4-methyl-2-oxopentanoate on protein degradation in incubated limb muscles of different fibre types from both immature and adult rats. To determine the specificity of an antiproteolytic effect of this compound, we also measured rates of protein synthesis and degradation in limb muscles incubated with 3-methylvalerate, the irreversibly decarboxylated product of 4-methyl-2-oxopentanoate, and with the 2-oxo acids of valine and isoleucine. Finally, the metabolism of branchedchain amino acids, 4-methyl-2-oxopentanoate and 3-methylvalerate was examined to determine whether any effects of these compounds on muscle proteolysis could be related to differences in their metabolism.
Experimental
Male Sprague-Dawley rats were obtained from Charles River Breeding Laboratory Inc. and maintained on Purina RMH 1000 (Agway Country Foods) chow and water ad libitum.
Rates of protein synthesis and degradation were measured in incubated soleus and extensor digitorum longus muscles obtained from fed, immature rats weighing less than 75g and in epitrochlearis muscles from fed adult rats weighing 200-220g by using procedures described previously (Clark & Mitch, 1983a,b) . After induction of anaesthesia with pentobarbital (5mg/l00g body wt.), the muscles were removed and incubated at 37°C in gassed with 2/Co02 (19: 1) and before incubation the pH was checked and adjusted to 7.4 when necessary. After a 30-min equilibration period, the muscles were transferred to flasks containing fresh medium, regassed, and incubated for 2h. Muscles were then removed and 2ml of medium was added to 0.5ml of cold 50% (w/v) trichloroacetic acid so that tyrosine and phenylalanine concentrations could be measured fluorometrically (Andrews et al., 1973; Faulkner, 1965; Waalkes & Udenfriend, 1957) . In incubations containing L-cycloserine, HNO3 and the nitroso-2-naphthol reagents were mixed before adding the sample of medium since L-cycloserine prevents the reaction of tyrosine with these reagents (Tischler et al., 1982 (Clark & Mitch, 1983a,b; Fulks et al., 1975) have found that there is rapid equilibration between the intra-and extra-cellular specific radioactivity of [U-14C] phenylalanine.
Muscle protein degradation was calculated as the rate of release of tyrosine into the medium during incubation with 0.5mM-cycloheximide (Fulks et al., 1975) . Tyrosine release was measured because this amino acid is neither synthesized nor degraded by muscle. Moreover, it does not accumulate intracellularly during the experimental period (Buse & Weigand, 1977; Clark & Mitch, 1983a) ; this was confirmed in the muscles used in these studies (results not shown).
Rates of uptake and catabolism of 3-methylvalerate, 4-methyl-2-oxopentanoate, leucine, valine and isoleucine were calculated by measuring the radioactivity recovered in protein, in the intracellular space of muscle and as 14CO2 evolved during incubation with the respective radiolabelled compounds. To calculate the intracellular concentration of radiolabelled compounds (Morgan et al., 1971) , the extracellular spaces of soleus, extensor digitorum longus, and epitrochlearis muscles were determined with [14C]inulin. These values were 28 + 2% for soleus (n = 5), 27 + 3% for extensor digitorum longus (n = 5) and 24 + 3% for epitrochlearis muscles (n = 5). Incorporation of radiolabelled compounds into muscle protein was measured by scintillation counting after washing trichloroacetic-acid-insoluble material successively with 10% (w/v) trichloroacetic acid and ethanol/ diethyl ether (1:1, v/v). The protein was dissolved in Soluene (Packard Instruments Co). and the radioactivity accumulated was divided by the extracellular specific radioactivity to calculate a rate of muscle protein synthesis (Odessey & Goldberg, 1972) .
To measure 14CO2 evolved, the flask was cooled on ice, and 2 ml of the medium was transferred by syringe to another stoppered flask containing 0.5ml of 50% (w/v) trichloroacetic acid and a suspended centre well containing 0.2ml of phenethylamine. This flask was incubated for 1 h and the 14CO2 trapped in the well was measured by scintillation counting.
To determine the extent of inhibition of leucine transmination during incubation with 5 mM-cycloserine, [1-I4C]leucine (0.5mM; 0.1 mCi/mmol) was added to the medium and, after the experimental period, the flask was cooled on ice, the muscle removed and a stopper with a suspended well containing phenethylamine was placed in the flask. Trichloroacetic acid was added and the 14CO2 evolved during leucine decarboxylation was measured. The centre well was then exchanged for one containing fresh phenethylamine and 0.5 ml of H202 was injected to convert 4-methyl-2-oxo[l-14C]pentanoate to 14CO2 plus 3-methylvalerate during an additional 1 h incubation (Odessey & Goldberg, 1979) . The sum of 14C02 measured in these two collections was used to calculate the rate of leucine transamination (Odessey & Goldberg, 1979; Tischler et al., 1982 Values are presented as means+S.E.M. Paired comparisons were used and P < 0.05 was judged to be significant statistically.
Results
Rates of protein synthesis and degradation in incubated soleus and extensor digitorum longus muscles varied from day to day, but as noted by others Libby & Goldberg, 1980; Lundholm et al., 1981) , the variability was smaller and more consistent within each experiment. One factor that could have contributed to this variability was differences in the dimensions of the muscle, causing variation in diffusion of oxygen and substrates . Preliminary studies revealed that soleus and extensor digitorum longus muscles obtained from rats weighing more than 75g had more variable rates of protein synthesis and degradation than did muscles from smaller rats. For this reason, immature rats were not studied if their weight exceeded 75 g. We found that the day-to-day coefficient of variation in the rate of protein degradation in epitrochlearis muscles (28-34mg) of rats weighing between 200 and 220g was 5.7%; for soleus and extensor digitorum longus, it was 14.4% and 11.3%, respectively.
The effects of leucine on protein synthesis and degradation in incubated soleus and extensor digitorum longus muscles are shown in Table 1 (Expt. 1). Leucine increased the rate of protein synthesis by 21% in soleus and 16% in extensor digitorum longus; it decreased the rate of protein degradation by 20% in soleus and 14% in extensor digitorum longus. To determine whether this effect on limb muscle protein degradation required conversion of leucine to 4-methyl-2-oxopentanoate, as it does in rat hemidiaphragms (Tischler et al., 1982) , transamination of leucine was inhibited by using 5mM-L-cycloserine (Table  1 , Expt. 2). L-Cycloserine was used instead of amino-oxyacetate because we found previously (Mitch, 1980) that the latter compound reduced protein synthesis in incubated muscle. In preliminary experiments, we confirmed that 5 mM-L-cycloserine inhibited transamination of [1-14C]leucine by more than 50% (Tischler et al., 1982) ; it did not (Clark & Mitch, 1983a To investigate whether the inhibition of protein degradation was unique for this branched-chain 2-oxo acid, the effects of 0.5mM concentrationsof4-methyl-2-oxopentanoate, 3-methyl-2-oxovalerate and 3-methyl-2-oxopentanoate on protein synthesis and degradation in three types of skeletal muscle were studied (Table 2 ). In soleus, extensor digitorum longus, and epitrochlearis muscles, 4-methyl-2-oxopentanoate consistently decreased protein degradation by 22, 15 and 16% respectively, but did not affect protein synthesis. During incubation of each muscle with 0.5 mM of the 2-oxo acids of valine or isoleucine, neither protein synthesis nor degradation was altered. Further studies revealed that incubation of epitrochlearis muscles with higher concentrations (1 and 5mM) of 3-methyl-2-oxovalerate or 3-methyl-2-oxopentanoate did not change the rate of protein degradation. In contrast, incubation with a lower concentration (0.25mM) of 4-methyl-2-oxopentanoate reduced protein degradation from 137.4+ 6.4 to 120.5 +6.9nmol of tyrosine/h per g (P <0.05 by paired analysis).
To determine whether inhibition of muscle protein degradation could be reproduced by 3-methylvalerate, the irreversibly decarboxylated product of4-methyl-2-oxopentanoate, we measured the dose-response relationship between this compound and protein degradation in incubated limb muscles of mature and immature rats. At 0.5 mM-3-methylvalerate, we measured CO2 production from this compound by using 3-methyl[1-14C]-valerate and found that it was 0.51 + 0.04 umol/h per g in soleus, 0. 19 + 0.02 umol/h per g in extensor digitorum longus and 0.29+0.02pmol/h per g in epitrochlearis muscles, indicating that the compound entered muscle and was degraded. However, 0.5mM-3-methylvalerate did not affect muscle protein degradation (Table 3) . When the concentration of 3-methylvalerate was 1 or 5mM, protein degradation decreased by 16-32% in soleus, extensor digitorum longus and epitrochlearis muscles. At lOmM-3-methylvalerate, protein degradation in epitrochlearis muscles decreased even further (P<0.05 by unpaired t-test) but in limb muscles of immature rats, protein degradation increased.
To compare the metabolism of 3-methylvalerate and 4-methyl-2-oxopentanoate, limb muscles were incubated with different concentrations of 3-methyl[l-14C]valerate or 4-methyl-2-oxo[l-14C]-pentanoate. As shown in Fig. 1 , the rate of CO2 released from 4-methyl-2-oxopentanoate was substantially greater than that evolved from 3-methylvalerate. The difference between the rates of CO2 evolved from 4-methyl-2-oxopentanoate and from 3-methylvalerate was remarkably constant when the extracellular concentration of these compounds was varied from 0.5 to 10mM.
Besides being converted to 14CO2, 4-methyl-2-oxo[l-14C]pentanoate can be transaminated to form [1-14C]leucine in muscle. At 0.5 mM-4-methyl-2-oxopentanoate, we calculated that the intracellular concentration of leucine plus its 2-oxo acid was 0.40 + 0.02 pmol/ml (Table 4) while the rate of incorporation of 4-methyl-2-oxopentanoate into bated with a branched-chain amino acid labelled at C-1, radioactivity in the intracellular space would reflect the concentrations of the amino acid plus its 2-oxo acid. Subtraction of this value from the intracellular concentration of radiolabelled compounds arising during incubation with the U-14C-labelled branched-chain amino acid (at the same concentration and specific radioactivity) would yield an estimate of the intracellular concentration of intermediates arising after decarboxylation of the 2-oxo acid. During incubation of epitrochlearis muscles with 1 mM-leucine, the intracellular concentration of metabolites formed after decarboxylation of 4-methyl-2-oxopentanoate was calculated to be 0.91 pmol/ml ( (Table 4) . Leucine is taken up and decarboxylated more rapidly and products arising from its degradation accumulate intracellularly to a greater extent compared with valine or isoleucine. Isovaleryl-CoA has been shown to inhibit branched-chain oxo acid dehydrogenase activity in kidney and liver (Randle et al., 1981) . To determine whether 3-methylvalerate inhibited decarboxylation of 4-methyl-2-oxopentanoate in skeletal muscle, we incubated epitrochlearis muscles with 4-methyl-2-oxo[1-14C]pentanoate (0.5mM) and different concentrations of 3-methylvalerate. Production of CO2 was significantly inhibited by the addition of 0.5mM-3-methylvalerate (0.77+0.06 to 0.54+0.04pmol/h per g; P < 0.05); the degree of inhibition of CO2 production did not increase when the concentration of 3-methylvalerate was raised either to 1mM (0.56+0.05jmol/h per g) or 5mM (0.52 + 0.03 ymol/h per g). In these same experiments, protein degradation was not depressed further by the addition of 3-methylvalerate to 4-methyl-2-oxopentanoate in the medium. Thus, we found that 0.5 mM-3-methylvalerate inhibited decarboxylation, but, as shown in Table 3 , 0.5 mM-3-methylvalerate did not inhibit proteolysis.
Discussion
These results indicate that the inhibitory effect of leucine on protein degradation in limb muscles of the rat, as in the hemidiaphragm (Tischler et al., 1982) , requires its transamination to the 2-oxo acid. Incubation with 0.5 mM-4-methyl-2-oxopentanoate decreased protein degradation by 15-22% in muscles of both adult and immature rats, but concentrations of the 2-oxo acids of valine and isoleucine as high as 5mM did not change muscle protein degradation. 3-Methylvalerate, the irreversibly decarboxylated product of 4-methyl-2-oxopentanoate, also decreased proteolysis, but only when the concentration was at least 1 mM (Table 3 ). In contrast, protein degradation was inhibited by the 2-oxo acid of leucine at 0.25mM concentration.
The mechanism by which 4-methyl-2-oxopentanoate reduces muscle proteolysis is unclear. The observation that 3-methylvalerate inhibited the decarboxylation of the 2-oxo acid of leucine and also decreased muscle protein degradation ( Table 3 ) could mean that the antiproteolytic effect of 3-methylvalerate was a consequence of increased intracellular levels of 4-methyl-2-oxopentanoate. This appears unlikely for two reasons. Firstly, 0.5 mM-3-methylvalerate inhibited 4-methyl-2-oxopentanoate decarboxylation in epitrochlearis muscles by 30% but did not affect the rate of protein degradation. As the concentration of 3-methylvalerate was raised to 1 and 5mM, inhibition of decarboxylation did not increase further, even though muscle protein degradation was progressively inhibited (Table 3) . Therefore, these two effects of 3-methylvalerate on muscle metabolism appear to be independent. Secondly, the 2-oxo acids of valine and isoleucine also inhibit 4-methyl-2-oxopentanoate decarboxylation in muscle (Odessey & Goldberg, 1979; Smith et al., 1983) yet in our experiments, 0.5-5 mm concentrations of these compounds did not inhibit proteolysis. These observations provide indirect evidence that the antiproteolytic effect of the 2-oxo acid of leucine in muscle is not related to increasing intracellular levels of the compound. Because 4-methyl-2-oxopentanoate is rapidly transaminated to leucine (Rhead et al., 1981) or decarboxylated (Fig. 1) to isovaleryl-CoA in muscle, proof that 4-methyl-2-oxopentanoate has a unique inhibitory effect on muscle protein degradation would require blocking both enzymatic reactions. Unfortunately, we and others (Smith et al., 1977) have found that amino-oxyacetate and cycloserine do not inhibit branched-chain amino acid transamination effectively in the presence of 4-methyl-2-oxopentanoate, and non-toxic inhibitors of branchedchain amino acid dehydrogenase are not available. Thus, we cannot exclude the possibility that muscle protein degradation can be specifically inhibited by changes in the intracellular concentration of 4-methyl-2-oxopentanoate.
The antiproteolytic effect of the 2-oxo acid of leucine is most likely caused by the intracellular accumulation of a product of its catabolism. This would be consistent with the observation that concentrations of 3-methylvalerate 2 1 mm led to accumulation of 3-methylvalerate and its metabolites in intracellular fluid (0.95 ymol/ml; 0.30Mmol/ml with 0.5 mM-leucine and increased to 0.91 umol/ml with 1 mM-leucine. These results contrast sharply with those obtained with 1 mMvaline, which did not affect proteolysis; the intracellular concentration of products arising after decarboxylation of 3-methyl-2-oxovalerate was only 0.08pmol/ml (Table 4) . Thus, the antiproteolytic effect of the 2-oxo acid of leucine, which is not shared by valine or isoleucine (Buse & Reid, 1975; Fulks et al., 1975; Tischler et al., 1982) or their 2-oxo acids (Table 2) , could be linked to the intracellular accumulation of a metabolite arising after decarboxylation of 4-methyl-2-oxopentanoate.
The greater sensitivity of muscle proteolysis to 4-methyl-2-oxopentanoate (Table 2 ) could be explained as follows. Firstly, the rate of 4-methyl-2-oxopentanoate uptake into muscle was found to be greater than that of 3-methylvalerate. As shown in Fig. 1 , the rate of CO2 production from 4-methyl-2-oxopentanoate was always greater than the rate from 3-methylvalerate, as was its utilization calculated as the sum of CO2 production, intracellular accumulation, and incorporation into protein (Table 4) . Secondly, the catabolism of 3-methylvalerate could be limited because it may not be readily charged with CoA after it enters muscle. The more rapid catabolism of 4-methyl-2-oxopentanoate (Fig. 1, Table 4 ) would lead to a greater accumulation of its catabolic products. Tischler (1980) reported that protein degradation is inhibited and the NADH/NAD+ ratio is increased when rat hemidiaphragms are incubated with leucine or its 2-oxo acid. This led him to suggest that the antiproteolytic effect of 4-methyl-2-oxopentanoate is linked to changes in the redox state of muscle. Our observations suggest that the cellular redox state and the rate of muscle protein degradation may not be closely linked. We found that 1 mM-3-methylvalerate decreased proteolysis in incubated epitrochlearis muscles while it inhibited 4-methyl-2-oxopentanoate decarboxylation. A lower rate of decarboxylation of 4-methyl-2-oxopentanoate would decrease NADH formation and the NADH/NAD+ ratio. Moreover, if 3-methylvalerate were converted to isovaleryl-CoA and then catabolized, this would consume reducing equivalents and decrease the NADH/NAD+ ratio further. In addition, we found that incubation of muscle with concentrations of 3-methyl-2-oxovalerate as high as 5mM did not change protein degradation, even though catabolism of this 2-oxo acid of valine (Table 4) would result in a net increase in cellular NADH (Smith et al., 1983) . Finally, incubation of epitrochlearis muscles with 2mM-pyruvate, which increased lactate production (+7.3 ± 2.2pmol/h per g) and therefore would consume NADH and decrease the NADH/NAD+ ratio, did not change the rate of proteolysis (-8 .3 ± 5 6nmol of tyrosine/h per g; n = 1 1).
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The potential therapeutic benefit of the 2-oxo acid of leucine has been suggested by clinical studies of catabolic conditions. Infusion of 4-methyl-2-oxopentanoate decreased urea production and improved nitrogen balance without producing adverse effects in starving, obese humans (Mitch et al., 1981) and in post-operative patients (Sapir et al., 1983) . In these same studies, infusion of leucine did not improve nitrogen balance. In addition, supplements of branchedchain 2-oxo acids containing large amounts of 4-methyl-2-oxopentanoate have been reported to decrease the rate of 3-methylhistidine excretion by patients with Duchenne's muscular dystrophy (Stewart et al., 1982) . Based on these reports and the finding that muscle protein degradation in vitro is more sensitive to 4-methyl-2-oxopentanoate than to 3-methylvalerate and is unaffected by other branched-chain 2-oxo acids, it would appear that the 2-oxo acid of leucine, rather than leucine, 3-methylvalerate, 3-methyl-2-oxovalerate or 3-methyl-2-oxopentanoate, would be the most likely compound to reduce protein hypercatabolism in vivo.
